268 studies found for:    "Expanded Access" [STUDY-TYPES]
Show Display Options
Rank Status Study
21 Available Expanded Access Protocol (EAP) Using the CliniMACS® Device for Pediatric Haplocompatible Donor Stem Cell Transplant
Conditions: Acute Lymphoblastic Leukemia;   Acute Myeloid Leukemia;   Chronic Myeloid Leukemia;   Myelodysplastic Syndrome;   Lymphomas;   Bone Marrow Failure;   Hemoglobinopathy;   Immune Deficiency;   Osteopetrosis;   Cytopenias;   White Blood Cell Abnormalities;   Red Blood Cell Abnormalities
Intervention: Biological: CD34+ enriched, T Cell Depleted donor stem cell product
22 Unknown  Treatment of Lambert-Eaton Syndrome With 3,4 Diaminopyridine
Condition: Lambert-Eaton Myasthenic Syndrome
Intervention: Drug: 3,4 diaminopyridine
23 No longer available Expanded Access Program of AMN107 in Imatinib-resistant or Intolerant Adult Patients With Chronic Myeloid Leukemia
Condition: Chronic Myeloid Leukemia
Intervention: Drug: AMN107
24 Approved for marketing Phase II Clinical Study of the Safety and Efficacy of the Relay Thoracic Stent-Graft
Conditions: Thoracic Aortic Aneurysm;   Penetrating Ulcers
Intervention: Device: Relay Thoracic Stent-Graft
25 Approved for marketing Safety and Efficacy of Varicella Zoster Immune Globulin (Human) VariZIG in Patients at Risk of Varicella Infection
Condition: Varicella
Intervention: Drug: VariZIG™
26 Available Omegaven Expanded Access Protocol
Condition: Parenteral Nutrition Associated Liver Disease
Intervention: Drug: Omegaven
27 Available Compassionate Use of 131I-MIBG for Patients With Malignant Pheochromocytoma
Conditions: Pheochromocytoma;   Paraganglioma
Intervention: Drug: 131 I-Metaiodobenzylguanidine (131 I-MIBG)
28 Available 68Ga DOTA-TATE PET/CT in Somatostatin Receptor Positive Tumors
Conditions: Carcinoid Tumors;   Islet Cell (Pancreatic NET);   Other Neuroendocrine Tumors
Intervention: Drug: 68Ga-DOTA TATE
29 Unknown  Weight-bearing Measuring Device to Determine Normative Percentage Body-Weight/Weight-Bearing Values and Weight-bearing Gait Characteristics
Conditions: Percentage Body-Weight;   Weight-Bearing Values;   Weight-bearing Gait Characteristics
Intervention: Device: SmartStep insole
30 Approved for marketing Early Access of MK0518 in Combination With an Optimized Background Antiretroviral Therapy (0518-023)
Condition: HIV Infections
Intervention: Drug: raltegravir
31 Available International Expanded Access Program to Provide Ramucirumab for the Treatment of Metastatic Gastric Cancer
Conditions: Metastatic Gastric Cancer;   Metastatic Adenocarcinoma of the Gastroesophageal Junction
Intervention: Biological: Ramucirumab
32 Unknown  Hypercalciuria and Calcium Stone Disease in Caucasian Patients
Conditions: Hypercalciuria;   Calcium Stone Disease
Interventions: Radiation: Radiological testing;   Genetic: Pediatric Urologic DNA and History Repository
33 Unknown  Efficacy and Safety Study of Neoadjuvant Chemotherapy for Local Advanced Triple Negative Breast Cancer Patients
Condition: Triple Negative Local Advanced Breast Cancer
Intervention: Drug: docetaxel oxaliplatin
34 Temporarily not available Standardization Research of TCM Syndrome Differentiation and Treatment on Advanced Breast Cancer
Conditions: Breast Cancer;   Bone Metastasis
Intervention: Dietary Supplement: Chinese Herbs
35 Available Compassionate Use Protocol for the Treatment of Autoinflammatory Syndromes
Conditions: Chronic Atypical Neutrophilic Dermatosis With Lipodystrophy and Elevated Temperature (CANDLE);   Juvenile Dermatomyositis (JDM);   Stimulator of Interferon Genes (STING)-Associated Vasculitis With Onset in Infancy (SAVI)
Intervention: Drug: Baricitinib
36 Unknown  Expanded Access Protocol Using I131-MIBG
Conditions: Neuroblastoma;   Pheochromocytoma;   Paraganglioma
Intervention: Radiation: I-131 MIBG
37 Available Regorafenib in Subjects With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy
Condition: Colorectal Neoplasms
Intervention: Drug: Regorafenib (BAY73-4506)
38 No longer available Compassionate Use of Metvix® (Methyl Aminolevulinate) Photodynamic Therapy (PDT) in Subjects With Field Actinic Keratoses, Large/Multiple Superficial Basal Cell Carcinomas (BCCs), or Bowen's Disease
Conditions: Field Actinic Keratoses;   Basal Cell Carcinoma;   Bowen's Disease
Intervention: Drug: Metvix (methyl aminolevulinate)
39 Approved for marketing Access Program With Denileukin Diftitox for the Treatment of Patients Currently Receiving Treatment With Commercially Available (Ontak)
Condition: Cancer
Intervention: Drug: Denileukin diftitox (ONTAK)
40 Available 131-I-MIBG Therapy for Refractory Neuroblastoma and Metastatic Pheochromocytoma
Conditions: Neuroblastoma;   Metastatic Pheochromocytoma
Interventions: Drug: 131 I-Metaiodobenzylguanidine (131 I-MIBG);   Drug: 131 I-MIBG

Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results
Indicates status has not been verified in more than two years